Tepotinib hydrochloride is a Small Molecule owned by Merck, and is involved in 23 clinical trials, of which 16 were completed, 6 are ongoing, and 1 is planned.
Tepotinib hydrochloride (MSC-2156119J) is a c-Met inhibitor. The drug candidate inhibit HGF/c-Met signaling thus, deactivating multiple signal transduction pathways including the Src/focal adhesion kinase (FAK) pathway, the p120/signal transducer and activator of transcription (STAT) 3 pathways, the phosphoinositide-3 kinase (PI3K)/Akt pathway, and the Ras/MEK pathway. The Src/FAK pathway regulates cell adhesion and migration. The drug candidates possess marked anti-angiogenic activity and directly inhibit the proliferation and migration of various cancer cell types..
The revenue for Tepotinib hydrochloride is expected to reach a total of $5.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tepotinib hydrochloride NPV Report.
Tepotinib hydrochloride is currently owned by Merck.
Tepotinib hydrochloride Overview
Tepotinib hydrochloride (Tepmetko) is anti neoplastic agent. It is formulated as film coated tablets for oral route of administration. Tepmetko is indicated for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. Tepmetko is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Tepotinib hydrochloride (Tepmetko, MSC-2156119J) is under development for the treatment of advanced gastric cancer and gastroesophageal junction carcinomas (AGC/GEJCs), colorectal cancer, recurrent glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma, breast cancer, renal cell cancer, gastric cancer, head and neck cancer, other solid tumors, advanced hepatocellular carcinoma, metastatic non-small cell lung cancer and metastatic non-squamous non-small cell lung cancer. The drug candidate is administered orally in the form of film coated tablet and capsule. The drug candidate acts by down-regulating the expression of c-Met. It was also under development for the treatment of metastatic colorectal cancer (mCRC).
Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.
Quick View – Tepotinib hydrochloride
|Highest Development Stage|